Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H12N4 |
Molecular Weight | 140.1863 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C1N2CN3CN1CN(C2)C3
InChI
InChIKey=VKYKSIONXSXAKP-UHFFFAOYSA-N
InChI=1S/C6H12N4/c1-7-2-9-4-8(1)5-10(3-7)6-9/h1-6H2
Molecular Formula | C6H12N4 |
Molecular Weight | 140.1863 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/24689705Curator's Comment: description was created based on several sources, including, http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/016151s025lbl.pdf
Sources: http://www.ncbi.nlm.nih.gov/pubmed/24689705
Curator's Comment: description was created based on several sources, including, http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/016151s025lbl.pdf
Methenamine is an antibacterial agent for preventing recurrent urinary tract infection. It can be used as methenamine hippurate or methenamine mandelate preparations and is United States Food and Drug Administration-approved. Methenamine exerts its activity because it is hydrolyzed to formaldehyde in acid urine.
Originator
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | UREX Approved UseFOR URAMIT MB™: URAMIT MB™ is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures. Launch Date-7.8710399E10 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
34 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7076604/ |
1 g 2 times / day multiple, oral dose: 1 g route of administration: Oral experiment type: MULTIPLE co-administered: |
METHENAMINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
177 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7076604/ |
1 g 2 times / day multiple, oral dose: 1 g route of administration: Oral experiment type: MULTIPLE co-administered: |
METHENAMINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7076604/ |
1 g 2 times / day multiple, oral dose: 1 g route of administration: Oral experiment type: MULTIPLE co-administered: |
METHENAMINE serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
1 g 2 times / day multiple, oral Recommended Dose: 1 g, 2 times / day Route: oral Route: multiple Dose: 1 g, 2 times / day Sources: |
healthy, 24-65 n = 10 Health Status: healthy Age Group: 24-65 Sex: M+F Population Size: 10 Sources: |
|
1 g single, oral Recommended |
healthy, 24-65 n = 10 Health Status: healthy Age Group: 24-65 Sex: M+F Population Size: 10 Sources: |
|
8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
Other AEs: Bladder irritation, Micturition painful... Other AEs: Bladder irritation Sources: Micturition painful Micturition frequency Albuminuria Hematuria |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Albuminuria | 8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
|
Bladder irritation | 8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
|
Hematuria | 8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
|
Micturition frequency | 8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
|
Micturition painful | 8 g 1 times / day multiple, oral Overdose Dose: 8 g, 1 times / day Route: oral Route: multiple Dose: 8 g, 1 times / day Sources: |
unhealthy Health Status: unhealthy Condition: Urinary tract infections Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Antimicrobial activity of four root canal sealers against endodontic pathogens. | 2001 Dec |
|
Effects of chlorhexidine gluconate as an endodontic irrigant on the apical seal: short-term results. | 2001 Dec |
|
Post retention: the effect of sequence of post-space preparation, cementation time, and different sealers. | 2001 Dec |
|
Plaque-like structures and arteriosclerotic changes in "diffuse neurofibrillary tangles with calcification" (DNTC). | 2001 Dec |
|
Wnt/Frizzled activation of Rho regulates vertebrate gastrulation and requires a novel Formin homology protein Daam1. | 2001 Dec 28 |
|
Localization of a mammalian homolog of diaphanous, mDia1, to the mitotic spindle in HeLa cells. | 2001 Feb |
|
Effect of ultrasonic vibration and various sealer and cement combinations on titanium post removal. | 2001 Jan |
|
Identification of a carboxyl-terminal diaphanous-related formin homology protein autoregulatory domain. | 2001 Jan 26 |
|
Toward designed assembly of microporous coordination networks constructed from silver(I)-hexamethylenetetramine layers. | 2001 Jul 2 |
|
Setting times for endodontic sealers under clinical usage and in vitro conditions. | 2001 Jun |
|
Modification of the levels of polyphenols in wort and beer by addition of hexamethylenetetramine or sulfite during mashing. | 2001 Nov |
|
Determination of the enrichment of the hydrogen bound to carbon 5 of glucose on 2H2O administration. | 2001 Oct 15 |
|
Genes and proteins in renal development. | 2002 |
|
Formins initiate new actin filaments. | 2002 Aug |
|
Invasive Aspergillosis in Italian AIDS patients. | 2002 Dec |
|
A Formin Homology protein and a profilin are required for cytokinesis and Arp2/3-independent assembly of cortical microfilaments in C. elegans. | 2002 Dec 23 |
|
Dramatic rate acceleration of the Baylis-Hillman reaction in homogeneous medium in the presence of water. | 2002 Dec 26 |
|
Delphilin: a novel PDZ and formin homology domain-containing protein that synaptically colocalizes and interacts with glutamate receptor delta 2 subunit. | 2002 Feb 1 |
|
Ground-glass hepatocytes in fibrinogen storage disease in Japanese Black calves. | 2002 Feb-Apr |
|
A 1:1 adduct of hexamethylenetetramine and 4-hydroxy-3-methoxybenzaldehyde. | 2002 Jan |
|
Hexamethylenetetraminium 2,4,6-trinitrophenolate. | 2002 Jan |
|
Evaluation of lectin staining in the diagnosis of fungal keratitis in an experimental rabbit model. | 2002 Jan 25 |
|
Cell polarity: following formin function. | 2002 Jan 8 |
|
Monolithic scavenger resins by amine functionalizations of poly(4-vinylbenzyl chloride-co-divinylbenzene) PolyHIPE materials. | 2002 Jul 25 |
|
Primary evaluation of methenamine as a NPN compound with probable effects on increasing ruminal escaped protein. | 2002 Jun |
|
Vibrational frequencies and structural determinations of hexamethylenetetraamine. | 2002 May |
|
Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178). | 2002 May 22 |
|
Hexamethylenetetramine-4-nitrocatechol-water (1/2/1). | 2002 Nov |
|
Dimethylsilane polyamines: cytostatic compounds with potentials as anticancer drugs. II. Uptake and potential cytotoxic mechanisms. | 2002 Nov-Dec |
|
Syntheses of two new 1D and 3D networks of Cu(II) and Co(II) using malonate and urotropine as bridging ligands: crystal structures and magnetic studies. | 2003 Apr 21 |
|
Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine. | 2003 Feb |
|
ForC, a novel type of formin family protein lacking an FH1 domain, is involved in multicellular development in Dictyostelium discoideum. | 2003 Feb 15 |
|
Adducts of hexamethylenetetramine with ferrocenecarboxylic acid and ferrocene-1,1'-dicarboxylic acid: multiple disorder in space groups Fmm2 and Cmcm. | 2003 Jul |
|
The Formin family protein, formin homolog overexpressed in spleen, interacts with the insulin-responsive aminopeptidase and profilin IIa. | 2003 Jul |
|
Two bis(ammonium) 1,5-naphthalenedisulfonate salts. | 2003 Jun |
|
Prognostic significance of microvascular thrombosis in donor kidney allograft biopsies. | 2003 Jun 15 |
|
Immunofluorescence of the epizootic ulcerative syndrome pathogen, Aphanomyces invadans, using a monoclonal antibody. | 2003 Jun 20 |
|
Detection of sugar syrups in apple juice by delta(2)H per thousand and delta(13)C per thousand analysis of hexamethylenetetramine prepared from fructose. | 2003 Mar 26 |
|
[Quantitative assessment of the biological activity of chemicals by soil microbial associations]. | 2003 May-Jun |
|
Activation of the Rac-binding partner FHOD1 induces actin stress fibers via a ROCK-dependent mechanism. | 2003 Oct 3 |
Patents
Sample Use Guides
One tablet (1 g) twice daily for adults and children over 12 years of age. One-half tablet or one tablet (0.5 or 1 g) twice daily for children 6 to 12 years of age.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/7028634
The antibacterial activity of methenamine and two of its organic acid salts was compared by continuous turbidimetric monitoring of static cultures exposed to the drugs and in an in vitro model of the treatment of bacterial cystitis. At pH 5.5, concentrations of 32 to 125 mg methenamine per 1 caused some inhibition of bacterial growth (Klebsiella aerogenes), but 250 to 500 mg/l were needed to suppress growth overnight. Methenamine hippurate was found to be less active than methenamine itself, whereas methenamine mandelate was as active as the parent compound.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sun Dec 18 18:01:39 UTC 2022
by
admin
on
Sun Dec 18 18:01:39 UTC 2022
|
Record UNII |
J50OIX95QV
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 520.2280
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
||
|
WHO-VATC |
QJ01XX55
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
||
|
EPA PESTICIDE CODE |
45501
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
||
|
WHO-VATC |
QJ01XX05
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
||
|
WHO-VATC |
QR01AX01
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
||
|
WHO-ATC |
J01XX05
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
||
|
NCI_THESAURUS |
C255
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
||
|
WHO-ATC |
R01AX01
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
||
|
JECFA EVALUATION |
INS-239
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-239
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
||
|
LIVERTOX |
NBK567340
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C61841
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
DB06799
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
Methenamine
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
M7308
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | Merck Index | ||
|
HEXAMETHYLENETETRAMINE
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
INS-239
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
SUB08845MIG
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
J50OIX95QV
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
100-97-0
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
CHEMBL1201270
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
26346
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
119
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
J50OIX95QV
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
6824
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
563
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
6832
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | RxNorm | ||
|
4101
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
202-905-8
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
3344
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
D008709
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
1409003
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
DTXSID6020692
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY | |||
|
403347
Created by
admin on Sun Dec 18 18:01:42 UTC 2022 , Edited by admin on Sun Dec 18 18:01:42 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |